We were especially interested in the potential application of HOXA9 as a biomarker, as promoter methylation of HOXA9 has been associated with aggressive tumor features, such as more advanced tumor stage, higher grade, larger tumor size and worse prognosis in patients with non-muscle-invasive bladder cancer [12,13,14]. Here, HOXA9 is linked to neoplasm.